Literature DB >> 8016831

The significance of prognostic factors for the resection of pulmonary metastases of breast cancer.

G Friedel1, A Linder, H Toomes.   

Abstract

Breast cancer is the most common malignant disease in women in Europe. In 15-25% of cases, the isolated formation of pulmonary metastases occurs. To date these metastases have been treated mainly by chemotherapy, radiotherapy, or hormone therapy. However, good results through pulmonary metastatic resection have been reported increasingly in recent times. From 1979 to 1992, 103 breast-cancer patients underwent surgery for suspected pulmonary metastases in our clinic. Intraoperatively in 88% of the whole group the metastases were confirmed, but in the other 12% they proved to be benign tumors or primary bronchial carcinomas. The operative therapy is standardized in our clinic. The approach is via a median or transverse sternotomy. Wedge resection is the normal procedure, undertaken in 55% of the cases. Complications, which were completely reversible in all cases, occurred in 3%. The 30-day mortality rate was 0%. In the whole patient population, the actuarial 5-year survival was 27%; it was 31% among the completely resected women, whereas no patient undergoing incomplete resection survived 5 years. Taking prognostic criteria into account, there are clear trends. When the disease-free interval exceeded 2 years, the actuarial 5-year survival was 33%, and if the receptor status of the primary tumor was positive, the 3-year survival was 61% compared to 38% for cases with negative receptor status. If a solitary metastasis was removed, the actuarial 5-year survival was 35% as opposed to 0% in cases with more than five metastases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8016831     DOI: 10.1055/s-2007-1016460

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  7 in total

Review 1.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

Review 2.  Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?

Authors:  Barbara A Pockaj; Nabil Wasif; Amylou C Dueck; Dennis A Wigle; Judy C Boughey; Amy C Degnim; Richard J Gray; Sarah A McLaughlin; Donald W Northfelt; Robert P Sticca; James W Jakub; Edith A Perez
Journal:  Ann Surg Oncol       Date:  2010-03-16       Impact factor: 5.344

3.  Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis.

Authors:  Jun Fan; Dali Chen; Heng Du; Cheng Shen; Guowei Che
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

4.  Full-thickness chest wall resection for locally recurrent breast cancer.

Authors:  Godehard Friedel; Thomas Kuipers; Corinna Engel; Christine Schopf; Stefanie Veit; Jutta Zoller; Thomas Kyriss; Michael Greulich; Heikki Toomes
Journal:  Thorac Surg Sci       Date:  2005-08-22

Review 5.  International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Authors:  Olivia Pagani; Elzbieta Senkus; William Wood; Marco Colleoni; Tanja Cufer; Stella Kyriakides; Alberto Costa; Eric P Winer; Fatima Cardoso
Journal:  J Natl Cancer Inst       Date:  2010-03-10       Impact factor: 13.506

6.  Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.

Authors:  Tessa G Steenbruggen; Michael Schaapveld; Hugo M Horlings; Joyce Sanders; Sander J Hogewoning; Esther H Lips; Marie-Jeanne T Vrancken Peeters; Niels F Kok; Terry Wiersma; Laura Esserman; Laura J van 't Veer; Sabine C Linn; Sabine Siesling; Gabe S Sonke
Journal:  JNCI Cancer Spectr       Date:  2021-02-04

7.  Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.

Authors:  Andrea Nicolini; Paola Ferrari; Riccardo Morganti; Angelo Carpi
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.